

PATENT APPLICATION
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Docket No: Q96974
Yoshinobu YAMAZAKI, et al.
Appln. No.: Not Yet Assigned
Confirmation No.: Not Yet Assigned Group Art Unit: Not Yet Assigned
Filed: September 22, 2006 Examiner: Not Yet Assigned
For: MEDICINE FOR PREVENTION OR TREATMENT OF FREQUENT URINATION OR URINARY INCONTINENCE

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§ 1.97 and 1.98

MAIL STOP AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No.: Not Yet Assigned

filng a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

Since the PCT Publications of citations (2) and (3) are written in Japanese, only the front pages including English abstracts are enclosed. Regarding the Japanese Patent publication of citation (7), only its abstract is available in English from IPDL of JPO, and the abstract is enclosed.

- (1) WO 02/069906 A2
- (2) WO 2003/024916 A1 & US 2004/242686 A1
- (3) WO 00/02846 A1 & US 6,538,152 B1
- (4) EP 1358889 A1
- (5) EP 1203582 A1
- (6) US 2001/004438 A1
- (7) JP 64-26517 A (family :none)

The two literature references were submitted in support of the amendments to the specification in the PRELIMINARY AMENDMENT.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

INFORMATION DISCLOSURE STATEMENT
U.S. Appln. No.: Not Yet Assigned

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,

/Peter D. Olexy/
Peter D. Olexy
Registration No. 24,513

SUGHRUE MION, PLLC
Telephone: (202) 293-7060
Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: September 22, 2006

Substitute for Form 1449 A & B/PTO				<i>Complete if Known</i>	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Application Number	Not Yet Assigned
				Confirmation Number	Not Yet Assigned
				Filing Date	September 22, 2006
				First Named Inventor	Yoshinobu YAMAZAKI
				Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet		1	of	1	Attorney Docket Number
					Q96974

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		Number	Kind Code ² (if known)		
/A.P./		US 2004/0242686	A1	12-02-2004	Isawa
/A.P./		US 2001/0044438	A1	11-22-01	Wyllie
		US 6,538,152	B1	03-25-2003	Tanaka
		US			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Translation ⁴
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)		
/A.P./		WO	02/069906	A2	Cell-Egy Pharmaceuticals, Inc.	English
		WO	2003/024916	A1	Kissei Pharmaceutical Co., Ltd.	Abstract
		WO	00/02846	A1	Kissei Pharmaceutical Co., Ltd.	Abstract
		JP	2001-288115	A	Yamanouchi Pharmaceutical Co., Ltd.	Abstract
		JP	2001-114679	A	Yamanouchi Pharmaceutical Co., Ltd.	Abstract
		JP	64-26517	A	Sankyo Co., Ltd.	Abstract
		EP	1 358 889	A1	Yamanouchi Pharmaceutical Co., Ltd.	English
/A.P./		EP	1 203 582	A1	Yamanouchi Pharmaceutical Co., Ltd.	English

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.			Translation ⁶
		KATSUYOSHI AKIYAMA, et al; KMD-3213, a Uroselective and Long-Acting α_2 -Adrenoceptor Antagonist, Tested in a Novel Rat Model, Journal of Pharmacology and Experimental Therapeutics, Vol. 291, No. 1; accepted for publication June 8, 1999			English
		HIROO TAKEDA, et al.; Role of the β_3 -Adrenoceptor in Urine Storage in the Rat: Comparison between the Selective β_3 -Adrenoceptor Agonist, CL316,243, and Various Smooth Muscle Relaxants'; Journal of Pharmacology and Experimental Therapeutics, Vol 293, No. 3; accepted for publication February 14, 2000			English

Examiner Signature	/Anna Pagonakis/	Date Considered	11/04/2008
--------------------	------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 509. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or follow the hyperlink from the title of the document to the [istract](#). ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to indicate here if English language Translation is attached.